GSK-3 and the neurodevelopmental hypothesis of schizophrenia

Author： Kozlovsky N.   Belmaker R.H.   Agam G.  

Publisher： Elsevier

ISSN： 0924-977X

Source： European Neuropsychopharmacology, Vol.12, Iss.1, 2002-02, pp. : 13-25

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

GSK3 Inhibitors and Disease

By  

Mini Reviews in Medicinal Chemistry, Vol. 9, Iss. 9, 2009-08 ,pp. : 1024-1029

Bentham Science Publishers

Access to resources Recommend Favorite

GSK-3 Inhibitors: Discoveries and Developments

By  

Current Medicinal Chemistry, Vol. 11, Iss. 6, 2004-03 ,pp. : 755-763

Bentham Science Publishers

Access to resources Recommend Favorite

Schizophrenia, the dopamine hypothesis and 2 -adrenoceptor antagonists

By Lindstrom L.H.  

Trends in Pharmacological Sciences, Vol. 21, Iss. 6, 2000-06 ,pp. : 198-199

Elsevier

Access to resources Recommend Favorite

Glutamate Hypothesis of Schizophrenia and Approach for Possible Therapeutic Drugs

By  

Current Medicinal Chemistry - Central Nervous System Agents, Vol. 4, Iss. 2, 2004-06 ,pp. : 147-154

Bentham Science Publishers

Access to resources Recommend Favorite

The Glutamate Hypothesis of Schizophrenia: Neuroimaging and Drug Development

By  

Current Pharmaceutical Biotechnology, Vol. 13, Iss. 8, 2012-06 ,pp. : 1500-1512

Bentham Science Publishers

Access to resources Recommend Favorite